Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

被引:38
作者
Rugo, Hope S. [1 ]
Brufsky, Adam M. [2 ]
Yood, Marianne Ulcickas [3 ,4 ]
Tripathy, Debu [5 ]
Kaufman, Peter A. [6 ]
Mayer, Musa [7 ]
Yoo, Bongin [8 ]
Abidoye, Oyewale O. [8 ]
Yardley, Denise A. [9 ,10 ]
机构
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[3] EpiSource LLC, Boston, MA USA
[4] Boston Univ, Sch Med, Sch Publ Hlth, Boston, MA 02118 USA
[5] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[7] AdvancedBC Org, New York, NY USA
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Tennessee Oncol PLLC, Nashville, TN USA
关键词
Racial disparities; HER2-positive; Metastatic breast cancer; registHER; Observational study; Treatment patterns; AFRICAN-AMERICAN WOMEN; PROSPECTIVE COHORT; INCREASED RISK; WHITE WOMEN; SURVIVAL; CARCINOMA; SUBTYPES; RACE; PREVALENCE; MORTALITY;
D O I
10.1007/s10549-013-2697-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited. registHER is a large, observational cohort study of patients (n = 1,001) with HER2-positive MBC diagnosed a parts per thousand currency sign6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow-up of 27 months). Demographics, treatment patterns, and clinical outcomes were described for black (n = 126) and white patients (n = 793). Progression-free survival (PFS) following first-line therapy and overall survival (OS) were examined. Multivariate analyses adjusted for baseline and treatment factors. Black patients were more likely than white patients to be obese (body mass index a parts per thousand yen30), to have diabetes, and to have a history of cardiovascular disease; they were also less likely to have estrogen receptor or progesterone receptor positive disease. In patients treated with trastuzumab, the incidence of cardiac safety events (grade a parts per thousand yen3) was higher in black patients (10.9 %) than in white patients (7.9 %). Unadjusted median OS and PFS (months) were significantly lower in black patients than in white patients (OS: black: 27.1, 95 % confidence interval [CI] 21.3-32.1; white: 37.3, 95 % CI 34.6-41.1; PFS: black: 7.0, 95 % CI 5.7-8.2; white: 10.2, 95 % CI 9.3-11.2). The adjusted OS hazard ratio (HR) for black patients compared with white patients was 1.29 (95 % CI 1.00-1.65); adjusted PFS HR was 1.29 (95 % CI 1.05-1.59). This real-world evaluation of a large cohort of patients with HER2-positive MBC shows poorer prognostic factors and independently worse clinical outcomes in black versus white patients. Further research is needed to identify potential biologic differences that could have predictive impact for black patients or that could explain these differences.
引用
收藏
页码:461 / 470
页数:10
相关论文
共 30 条
[1]   Lung carcinoma in African Americans [J].
Abidoye, Oyewale ;
Ferguson, Mark K. ;
Salgia, Ravi .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (02) :118-129
[2]   Breast cancer in African-American women: differences in tumor biology from European-American women [J].
Amend, Kandace ;
Hicks, David ;
Ambrosone, Christine B. .
CANCER RESEARCH, 2006, 66 (17) :8327-8330
[3]   The Prognostic Contribution of Clinical Breast Cancer Subtype, Age, and Race Among Patients With Breast Cancer Brain Metastases [J].
Anders, Carey K. ;
Deal, Allison M. ;
Miller, C. Ryan ;
Khorram, Carmen ;
Meng, Hong ;
Burrows, Emily ;
Livasy, Chad ;
Fritchie, Karen ;
Ewend, Matthew G. ;
Perou, Charles M. ;
Carey, Lisa A. .
CANCER, 2011, 117 (08) :1602-1611
[4]  
[Anonymous], 2006, COMMON TERMINOLOGY C
[5]   Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women [J].
Banegas, Matthew P. ;
Li, Christopher I. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) :1297-1304
[6]   Missed opportunities: Racial disparities in adjuvant breast cancer treatment [J].
Bickell, NA ;
Wang, JJ ;
Oluwole, S ;
Schrag, D ;
Godfrey, H ;
Hiotis, K ;
Mendez, J ;
Guth, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1357-1362
[7]   Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER [J].
Brufsky, Adam M. ;
Mayer, Musa ;
Rugo, Hope S. ;
Kaufman, Peter A. ;
Tan-Chiu, Elizabeth ;
Tripathy, Debu ;
Tudor, Iulia Cristina ;
Wang, Lisa I. ;
Brammer, Melissa G. ;
Shing, Mona ;
Yood, Marianne Ulcickas ;
Yardley, Denise A. .
CLINICAL CANCER RESEARCH, 2011, 17 (14) :4834-4843
[8]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[9]   Effects of Individual-Level Socioeconomic Factors on Racial Disparities in Cancer Treatment and Survival [J].
Du, Xianglin L. ;
Lin, Charles C. ;
Johnson, Norman J. ;
Altekruse, Sean .
CANCER, 2011, 117 (14) :3242-3251
[10]  
Estevez LG., 2003, AM J CANCER, V2, P169, DOI [10.2165/00024669-200302030-00002, DOI 10.2165/00024669-200302030-00002]